Dr. Sepp-Lorenzino is a highly accomplished scientific leader with a distinguished career in the development of innovative genetic medicines. She most recently served as the Chief Scientific Officer of Intellia Therapeutics, where she played a pivotal role in advancing the company's CRISPR-based pipeline. Prior to Intellia, she held leadership positions at Vertex Pharmaceuticals as Head of Nucleic Acid Therapies, and at Alnylam Pharmaceuticals where she led hepatic infectious disease programs and served as Entrepreneur-in-Residence. She began her industrial career at Merck & Co., leading RNAi and oncology drug discovery efforts.
Dr. Sepp-Lorenzino currently serves on the board of directors of Taysha Gene Therapies, Asklepios Biopharmaceutical (AskBio), Lexeo Therapeutics, URSA Medicines, the Oligonucleotide Therapeutics Society (OTS), and the American Society of Cell and Gene Therapy (ASGCT). She is the President Elect of OTS and she serves on the scientific advisory board of ThermoFisher Scientific, Galtec and Inverna Therapeutics. She holds a professional degree in Biochemistry from the University of Buenos Aires, Argentina, and earned her M.S. and Ph.D. in Biochemistry from New York University. She also contributes to the scientific community as an editorial board member of Nucleic Acid Therapeutics and Molecular Therapy Nucleic Acids.